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Hereditary sensory and autonomic
neuropathy type 1 (HSANI) caused
by a novel mutation in SPTLC2
ABSTRACT
Objective: To describe the clinical and neurophysiologic phenotype of a family with hereditary
sensory and autonomic neuropathy type 1 (HSANI) due to a novel mutation in SPTLC2 and to
characterize the biochemical properties of this mutation.
Methods: We screened 107 patients with HSAN who were negative for other genetic causes for
mutations in SPTLC2. The biochemical properties of a new mutation were characterized in cell-free
and cell-based activity assays.
Results: A novel mutation (A182P) was found in 2 subjects of a single family. The phenotype of the 2
subjectswas an ulcero-mutilating sensory-predominant neuropathy as described previously for patients
with HSANI, but with prominent motor involvement and earlier disease onset in the first decade of life.
Affected patients had elevated levels of plasma 1-deoxysphingolipids (1-deoxySLs). Biochemically, the
A182Pmutation was associated with a reduced canonical activity but an increased alternative activity
with alanine, which results in largely increased 1-deoxySL levels, supporting their pathogenicity.
Conclusion: This study confirms that mutations in SPTLC2 are associated with increased deoxySL
formation causing HSANI. Neurology 2013;80:2106–2111
GLOSSARY
AD 5 autosomal dominant; 1-deoxySL 5 1-deoxysphingolipid; FB1 5 Fumonisin B1; HSANI 5 hereditary sensory and
autonomic neuropathy type 1; SA 5 sphinganine; SO 5 sphingosine; SPT 5 serine palmitoyltransferase; wt 5 wild type.
Hereditary sensory and autonomic neuropathy type 1 (HSANI) is an autosomal dominant (AD)
sensory neuropathy complicated by ulcerations and amputations, with variable autonomic and
motor involvement.1 To date, mutations in 5 genes have been reported to cause AD HSANI.2–7
Mutations in the enzyme serine palmitoyltransferase (SPT) cause HSANI.2,3 SPT is a heter-
omeric enzyme composed of 3 subunits (SPTLC1–3) located at the outer membrane of the
endoplasmic reticulum.8,9 It catalyzes the first and rate-limiting step in de novo sphingolipid
synthesis: the condensation of L-serine and palmitoyl-coenzyme A. Mutations in SPTLC1
account for 12% of patients with HSAN.10 More recently, mutations in SPTLC2 were found
to cause HSANI with a similar phenotype.4 SPTLC1 and SPTLC2 mutations generally cause a
shift in the substrate specificity of SPT leading to the alternative use of L-alanine and L-glycine
over its canonical substrate L-serine.11,12 This forms an atypical category of 1-deoxysphingolipids
(1-deoxySLs) lacking the C1 hydroxyl group, which impedes their conversion into complex
sphingolipids but also their canonical degradation. Elevated 1-deoxySLs were found in the
plasma and lymphoblasts of patients with HSANI11 and plasma and tissues of transgenic HSANI
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mice.13 The 1-deoxySLs were shown to be neu-
rotoxic, blocking neurite formation in cultured
neurons.11
Herein, we report a novel HSANI mutation
in SPTLC2 associated with elevated plasma
1-deoxySLs. In vitro and cell culture studies
show that this mutant has reduced canonical
activity but forms high levels of 1-deoxySLs.
METHODS Standard protocol approvals, registrations,
and patient consents. Ethical approval for this study was obtained
from the Joint Medical and Ethics Committee at the National Hos-
pital for Neurology and Neurosurgery. Written informed consent
was obtained from all patients.
Patients. One hundred seven patients with HSAN were selected
from our inherited neuropathy database, including patients seen
in the National Hospital for Neurology and Neurosurgery
peripheral neuropathy clinics as well as patients whose DNA
was referred from other hospitals for diagnostic and research test-
ing. Most patients presented with distal progressive sensory loss,
with or without ulcero-mutilating complications or autonomic
dysfunction. Because of the overlap between Charcot-Marie-
Tooth type 2B and HSANI, we included patients with motor
involvement; however, sensory features were predominant. Diag-
nosis was based on clinical phenotype in addition to neurophys-
iology. All patients were negative for mutations in SPTLC1 and
most were also negative for mutations in RAB7,NGFB, FAM134B,
and NTRK1. Three hundred fifty-eight British control chromo-
somes were screened for control.
Patient assessment. Patients found to have mutations under-
went detailed clinical and neurophysiologic assessments including
the Charcot-Marie-Tooth Neuropathy Score 2.14 Nerve conduc-
tion studies were performed using standard technique.
Genetic sequencing. All 12 exons and flanking introns of SPTLC2
were amplified using Roche PCR reagents. Sequence reactions were
performed using the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) and resolved on an ABI 3730xl
Sequencer. For primers and primer conditions, see table e-1 on the
Figure 1 Pedigree of HSANI family with SPTLC2-A182P mutation
HSANI 5 hereditary sensory and autonomic neuropathy type 1; square 5 male; circle 5
female; diagonal line 5 deceased; filled symbol 5 affected; m/1 5 heterozygous for muta-
tion; arrow 5 proband; electropherogram of affected patient and control.
T
ab
le
1
C
lin
ic
al
d
et
ai
ls
P
at
ie
nt
A
g
e
la
st
ex
am
,y
S
ex
A
A
O
S
ym
p
to
m
s
at
on
se
t
P
os
it
iv
e
se
ns
or
y
sy
m
p
to
m
s
M
ot
or
U
L/
LL
S
en
so
ry
U
lc
er
o-
m
ut
ila
ti
ng
co
m
p
lic
at
io
ns
A
m
p
ut
at
io
ns
R
ef
le
xe
s
C
M
T
N
S
2
III
-2
6
3
F
1
0
N
um
b
fe
et
P
ai
nf
ul
ti
ng
lin
g
in
ha
nd
s
S
ev
er
e
di
st
al
U
L
an
d
LL
V
ib
to
kn
ee
s,
pi
n
ab
ov
e
w
ri
st
s
an
d
ab
ov
e
kn
ee
s
B
ur
ns
an
d
ul
ce
rs
N
o
B
ri
sk
U
L,
ab
se
nt
at
an
kl
es
2
5
/3
6
IV
-2
2
9
F
5
N
um
b
fe
et
N
o
M
ild
pr
ox
im
al
an
d
se
ve
re
di
st
al
U
L/
se
ve
re
di
st
al
LL
V
ib
to
an
kl
e,
pi
n
ab
ov
e
el
bo
w
an
d
ab
ov
e
kn
ee
B
ur
ns
an
d
ul
ce
rs
N
o
B
ri
sk
U
L,
re
du
ce
d
at
an
kl
e
2
7
/3
6
A
bb
re
vi
at
io
ns
:A
A
O
5
ag
e
at
on
se
t;
C
M
TN
S
2
5
C
ha
rc
ot
-M
ar
ie
-T
oo
th
N
eu
ro
pa
th
y
S
co
re
ve
rs
io
n
2
1
4
;L
L
5
lo
w
er
lim
bs
;U
L
5
up
pe
r
lim
bs
;V
ib
5
vi
br
at
io
n.
Neurology 80 June 4, 2013 2107
Neurology® Web site at www.neurology.org. Sequence variants were
confirmed by repeat sequencing.
PolyPhen2 (http://genetics.bwh.harvard.edu/pph/), SIFT
(http://blocks.fhcrc.org/sift/SIFT.html), and aGVGD (http://
agvgd.iarc.fr/) were used to predict the effect of the mutation
on protein function.
Cloning. The A182P was introduced into the SPTLC2 cDNA
by site-directed mutagenesis as described previously11 (see table e-2
for primers). All constructs were verified by sequencing.
Stable expression of SPTLC2wt and the A182P mutation
in HEK293 cells. HEK293 cells (ATCC, Manassas, VA) were
stably transfected with the empty vector (control), SPTLC2 wild
type (wt), or the A182P mutant as described previously.11 Expres-
sion of the constructs was confirmed by reverse transcriptase–PCR
and immune blotting (figure e-1).
Metabolic labeling assay. Transfected HEK293 cells were cul-
tured in Dulbecco’s modified Eagle medium for 3 days before
medium was changed to Dulbecco’s modified Eagle medium with-
out L-serine (Genaxxon BioScience, Ulm, Germany). After 2 hours
of preincubation, isotope-labeled (2,3,3-d3, 15N) L-serine (1 mM)
and (2,3,3,3)-d4–labeled L-alanine (5 mM) (Cambridge Isotope
Laboratories, Inc., Andover, MA) were added to the cells. In some
cases, cells were treated with Fumonisin B1 (FB1) (35 mM) as
described. Cells were harvested after 24 hours, counted (Z2 Coul-
ter Counter; Beckman Coulter, Brea, CA), and pelleted (800g,
5 minutes at 4°C). Pellets were stored at 220°C.
SPT in vitro activity assay and lipid-base extraction. SPT
in vitro activity was measured as described previously.15 In modifica-
tion to the original protocol, 64 mM L-serine or 320 mM L-alanine
(Sigma, St. Louis, MO) was used.
Acid-base extraction and analysis of sphingoid bases.
MetOH 500 mL including 200 pmol internal standard (d7-
sphinganine and d7-sphingosine; Avanti Polar Lipids, Alabaster,
AL) were added to 100 mL of plasma or frozen cell pellets resus-
pended in 100 mL phosphate-buffered saline. Lipid extraction was
performed for 1 hour at 37°C with constant agitation at 1,000 rpm
(Thermomixer Comfort; Eppendorf, Hamburg, Germany). Pre-
cipitated protein was removed by centrifugation (5 minutes at
16,000g). After transferring the supernatant into a new tube, lipids
were extracted and analyzed by liquid chromatography–mass spec-
trometry as described earlier.11
Statistics. One-way analysis of variance was used for statistical
analysis. Significance was verified by Bonferroni multiple correc-
tion. Unless otherwise stated, p values ,0.001 were considered
significant. Statistical analysis was performed using GraphPad
Prism 5 (GraphPad Software, La Jolla, CA).
RESULTS Genetics. Sequencing of SPTLC2 in 107
index patients with HSANI revealed a novel mutation
in one family. c.544G.C, A182P, was found in the
index case (figure 1, III-2); this mutation was not
present in 358 control chromosomes. One other
affected member of this family who was tested carried
the mutation (figure 1, IV-2).
Figure 2 Sphingoid (A) and deoxysphingoid (B) base levels
1-Deoxysphingolipids in plasma of patients and healthy controls. Significantly elevated
1-deoxysphingolipid levels were found for patients carrying the SPTLC2-A182P mutation.
Data are shown as means, with error bars representing SDs. SDs were calculated using 1-
way analysis of variance with Bonferroni multiple correction. n.s. 5 not significant; SA 5
sphinganine; SO 5 sphingosine. ***p , 0.001; ****p , 0.0001.
Table 2 Nerve conduction studies
Patient
Median Ulnar
Radial
Common peroneal
Sural
DML, ms CV, m/s CMAP, mV SAP, mV DML, ms CV, m/s CMAP, mV SAP, mV SAP, mV DML, ms CV, m/s CMAP, mV SAP, mV
III-2 3.5 32 4.5 NR 3.9 33 3.1 NR NR NR NR NR
IV-2 4.1 25 0.2 NR 4.1 29 0.3 NR NR 5.4 30 0.2
Abbreviations: CMAP 5 compound motor action potential; CV 5 conduction velocity; DML 5 distal motor latency; NR 5 not recordable; SAP 5 sensory
action potential.
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The A182P mutation affects a highly evolutionary
conserved amino acid; PolyPhen2 and SIFT both pre-
dict that this change would be damaging, whereas
aGVGD classifies the variant as class C25, where
C65 is most likely to interfere with function and
C0 less likely to interfere with function.
Clinical details. The family had AD inheritance (fig-
ure 1). Clinical features are documented in table 1.
Both patients had onset in the first decade, presenting
with reduced sensation in the feet, with later devel-
opment of motor weakness. Sensory loss occurred in a
glove and stocking distribution; pinprick perception
was affected to a greater extent than vibration percep-
tion, similar to patients with SPTLC1 mutations.16
Patient III-2 had painful tingling in the hands whereas
IV-2 had no history of pain. Sensory complications
including ulcers and accidental burns occurred in both
patients, and severe wasting and weakness were present
(figure e-2). There were no symptoms of hearing loss
or autonomic dysfunction.
Neurophysiology. Table 2 describes the neurophysiol-
ogy of the patients with HSANI. Although this was
predominantly an axonal neuropathy, motor conduc-
tion velocities in the upper limbs were slow (,38 m/s),
even in patient III-2 who had reasonable upper limb
motor amplitudes, a finding that we have previously
documented in our HSANI families with SPTLC1
mutations.16
Plasma sphingoid and deoxysphingoid base levels. Total
sphinganine (SA) or sphingosine (SO) levels showed
no difference between SPTLC2-A182P patients and
healthy controls, whereas the 1-deoxySL levels were
elevated in the plasma of the two A182P carriers.
Higher 1-deoxySL plasma levels were found in the
more severely affected patient, IV-2 (figure 2).
Figure 3 SPT activity in vitro (A, B) and in HEK293 cells (C, D)
In vitro SPT activity with L-serine (A) and L-alanine (B) measured in 1 mg total protein lysate extracted from HEK293 cells
expressing wt or mutant SPTLC2. (A) The A182P mutation leads to a significant decrease in keto-SA compared with the
SPTLC2wt-expressing control (p , 0.001). (B) The A182P mutation leads to a significant increase in keto-deoxySA com-
pared with the SPTLC2wt-expressing control (p , 0.0001). (C) SPT activity measured in HEK293 cells. SPT activity in the
SPTLC2wt is increased in the presence of FB1, whereas this increase is lost for the A182P mutant (p , 0.0001). Without
FB1, SPT activity is not different between mutant and SPTLC2wt. (D) Generation of deoxySLs in HEK293 cells. The A182P
mutation leads to a significant increase in deoxySL formation compared with SPTLC2wt cells (p, 0.0001). In the presence
of FB1, deoxySLs are also generated by SPTLC2wt cells (p , 0.001), but the formation was significantly higher in the
A182P cells (p , 0.0001). Data are shown as means, with error bars representing SDs. SDs were calculated using 1-way
analysis of variance with Bonferroni multiple correction. FB1 5 Fumonisin B1; deoxy-SA 5 deoxysphinganine; deoxy-SO 5
deoxysphingosine; deoxySL 5 deoxysphingolipid; SA 5 sphinganine; SO5 sphingosine; SPT5 serine palmitoyltransferase;
wt 5 wild-type.
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Effect of the SPTLC2-A182P mutation on SPT activity.
Most HSANI mutations in SPTLC1 and SPTLC2 are
associated with reduced canonical activity and increased
1-deoxySL formation.2–4,17 The A182P mutant showed
a 65% reduced in vitro activity with L-serine and a
3.5-fold increased activity with L-alanine (figure 3, A
and B). These results were confirmed by a metabolic
labeling assay using isotope-labeled (d3, 15N) L-serine
(1 mM) and (d4) L-alanine (5 mM), which leads to the
formation of isotope-labeled (M13)SA and (M13)de-
oxySA because one deuterium is lost during the con-
densation reaction.18 The assay was performed in the
presence or absence of FB1, an inhibitor for ceramide
synthase. The inhibition of ceramide synthase leads to
the accumulation of SA over time, which is a measure
for cellular SPT activity. In the presence of FB1, the
SPTLC2wt cells showed a 2- to 3-fold higher accumu-
lation of (M13)SA and (M13)deoxySA compared
with controls (figure 3, C and D). In the A182P cells,
the formation of (M13)SA was reduced 2- to 3-fold
(figure 3C). (M13)deoxySA formation was 15-fold
higher in A182P than in SPTLC2wt cells (figure
3D). In the absence of FB1, the sphingoid bases are
mostly metabolized into ceramides and complex sphin-
golipids, which results in a predominant release of
(M13)SO after acid hydrolysis (figure 3C). In contrast,
deoxySLs were predominantly present as (M13)deox-
ySA (figure 3D). Interestingly, in SPTLC2wt cells, the
total sum of isotope-labeled sphingoid bases was 50%
higher in FB1-treated than in nontreated cells. In the
absence of FB1, the activity with serine was the same in
A182P and SPTLC2wt cells (figure 3C). No isotope-
labeled 1-deoxySLs were found in control or SPTLC2wt
cells when FB1 was absent. However, labeled 1-deoxySLs
were formed in A182P cells, although total levels were
about 8-fold lower compared with FB1-treated A182P
cells (figure 3D). Because FB1 showed no effect on
SPT activity in vitro (data not shown), we assume that
the stimulatory effect of FB1 on SPT activity is indirect
and probably associated with a recently described met-
abolic feedback regulation.19–21
No differences in the spatial distribution were seen
between SPTLC2 and the A182P mutant. Immunohis-
tochemistry showed in both cases a colocalization with
the endoplasmic reticulum marker calnexin (figure e-3).
DISCUSSION Mutations in SPTLC1 are a well-
established cause of HSANI.2,3,16 An initial study of
12 families with HSANI did not find any patients
with mutations in SPTLC2.22 However, because of
the known association of SPT with HSANI, SPTLC2
remained a functional candidate and a later study
established that mutations in SPTLC2 were also asso-
ciated with HSANI.4 Our report provides genetic and
functional data demonstrating that a novel A182P
mutation found in one family is pathogenic, and gives
detailed clinical and neurophysiologic descriptions of
the phenotype. The age at onset in this family was
in the first decade, younger than is typically seen in
patients with HSANI. To date, 3 mutations in
SPTLC2 have been described (V359M, G382V,
and I504F).4 One of these was associated with early
onset in the first decade and other atypical features
such as motor conduction velocities in the demyelin-
ating range, suggesting a wide phenotypic spectrum
of HSANI.
Elevated blood 1-deoxySL levels were confirmed in
both A182P carriers; higher levels were found in the
more severely affected daughter than themother. In vitro,
the A182P mutant showed significantly reduced activity
with L-serine and increased activity with L-alanine. This
was confirmed by 2 metabolic labeling assays.
The combined genetic, clinical, and functional
data confirm the association of this novel SPTLC2
mutation with HSANI. It further supports the con-
cept that a pathologic 1-deoxySL formation underlies
the pathogenesis of HSANI, indicating that HSANI,
in contrast to most other inherited neuropathies, is a
metabolic disorder. The 1-deoxySLs are hereby relevant
HSANI biomarkers to validate the functional conse-
quences of genetic SPTLC1 and SPTLC2 variants.
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